D. Madar

发表

Pyrrolidine-constrained phenethylamines: The design of potent, selective, and pharmacologically efficacious dipeptidyl peptidase IV (DPP4) inhibitors from a lead-like screening hit.

G. L. Hamilton, K. Longenecker, H. Sham, 2007, Bioorganic & medicinal chemistry letters.

3,5-Bis(trifluoromethyl)pyrazoles: a novel class of NFAT transcription factor regulator.

Xiaoping Zhou, U. Warrior, C. Wegner, 2000, Journal of medicinal chemistry.

Inhibition of p56lckTyrosine Kinase by Isothiazolones

U. Warrior, Yung-wu Chen, P. Wiedeman, 1999 .

Discovery of 2-[4-{{2-(2S,5R)-2-cyano-5-ethynyl-1-pyrrolidinyl]-2-oxoethyl]amino]- 4-methyl-1-piperidinyl]-4-pyridinecarboxylic acid (ABT-279): a very potent, selective, effective, and well-tolerated inhibitor of dipeptidyl peptidase-IV, useful for the treatment of diabetes.

K. Longenecker, J. Segreti, H. Sham, 2006, Journal of medicinal chemistry.

Potential drug targets and progress towards pharmacologic inhibition of hepatic glucose production.

A. Souers, S. Richards, B. Szczepankiewicz, 2003, Current medicinal chemistry.

Synthesis of (+)-dynemicin A and analogs of wide structural variability: establishment of the absolute configuration of natural dynemicin A.

N. J. Tom, M. Fraley, S. Cohen, 1995, Chemistry & biology.

Prospects for pharmacologic inhibition of hepatic glucose production.

A. Souers, S. Richards, B. Szczepankiewicz, 2003, Current medicinal chemistry.

Correction to Structure-Guided Design of a Series of MCL-1 Inhibitors with High Affinity and Selectivity.

Scott A. Erickson, C. Tse, A. Petros, 2015, Journal of medicinal chemistry.

A Convergent Synthetic Route to (+)-Dynemicin A and Analogs of Wide Structural Variability

N. J. Tom, M. Fraley, Scott B. Cohen, 1997 .

Diisopropyl 2‐Allyl‐1,3,2‐dioxaborolane‐4,5‐dicarboxylate

Wei Wang, D. Madar, Guixia Liu, 2009 .

TOTAL SYNTHESIS OF (+)-DAMAVARICIN D

W. Roush, D. Madar, and D. Scott Coffey, 1997 .

Synthesis of highly functionalized naphthoate precursors to damavaricin D Observation of kinetically stable benzocyclohexadienones in the bromination reactions of highly functionalized β-naphthol derivatives

W. Roush, D. S. Coffey, D. Madar, 2001 .

Towards the synthesis of streptovaricin D: Synthesis of fully elaborated aromatic precursors and coupling with ansa chain fragments

W. Roush, D. Madar, 1993 .

Comparison of the oxidative folding of lysozyme at a high protein concentration using aromatic thiols versus glutathione.

W. Lees, D. Madar, Amar S Patel, 2009, Journal of biotechnology.

Insights into the Mechanism of DNA Cleavage by Dynemicin A as Revealed by DNA-Binding and -Cleavage Studies of Synthetic Analogs

N. J. Tom, M. Fraley, Scott B. Cohen, 1995 .

Discovery of ((4R,5S)-5-amino-4-(2,4,5- trifluorophenyl)cyclohex-1-enyl)-(3- (trifluoromethyl)-5,6-dihydro- [1,2,4]triazolo[4,3-a]pyrazin-7(8H)-yl)methanone (ABT-341), a highly potent, selective, orally efficacious, and safe dipeptidyl peptidase IV inhibitor for the treatment of type 2 diabetes.

K. Longenecker, H. Sham, R. Fryer, 2006, Journal of medicinal chemistry.

Structure-guided design of a series of MCL-1 inhibitors with high affinity and selectivity.

Scott A. Erickson, C. Tse, A. Petros, 2015, Journal of medicinal chemistry.

Crystal structures of DPP-IV (CD26) from rat kidney exhibit flexible accommodation of peptidase-selective inhibitors.

Vincent S Stoll, K. Longenecker, V. Stoll, 2006, Biochemistry.

Synthesis of N-arylated oxazolidinones via a palladium catalyzed cross coupling reaction. Application to the synthesis of the antibacterial agent Dup-721

P. Wiedeman, S. Djurić, Marina A. Pliushchev, 2001 .

4,4′‐Dimethoxytrityl Chloride

D. Madar, 2002 .

N-aryl-benzimidazolones as novel small molecule HSP90 inhibitors.

Jun Chen, Saul H Rosenberg, Xiaohong Song, 2010, Bioorganic & medicinal chemistry letters.

Inhibition of p56(lck) tyrosine kinase by isothiazolones.

U. Warrior, P. Wiedeman, J. Trevillyan, 1999, Archives of biochemistry and biophysics.

Discovery, structure-activity relationship, and pharmacological evaluation of (5-substituted-pyrrolidinyl-2-carbonyl)-2-cyanopyrrolidines as potent dipeptidyl peptidase IV inhibitors.

H. Sham, Xiaofen Li, D. Beno, 2006, Journal of Medicinal Chemistry.